GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Regeneron Pharmaceuticals
Regeneron is a biopharmaceutical company known for its breakthrough treatments for eye diseases (Eylea) and atopic dermatitis (Dupixent, in partnership with Sanofi). Its success is based on a strong research platform.
Share prices of companies in the market segment - Heart
Regeneron is one of the world's leading biotech companies, known for its eye treatments (Eylea) and dermatitis (Dupixent). We classify it as part of the Heart sector, and the chart below reflects the overall performance of this segment.
Broad Market Index - GURU.Markets
Regeneron is a leading biotech company known for its treatments for eye diseases, allergies, and cancer. Its focus on science makes it a key component of the GURU.Markets index. The chart below represents the entire market. See how Regeneron is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
REGN - Daily change in the company's share price Regeneron Pharmaceuticals
For Regeneron, a leading biotech company, daily price changes are a measure of its response to clinical trial results. While the graph of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Heart
Regeneron Pharmaceuticals, Inc. is a leading biotech company. This chart highlights the sector's high volatility. Comparing it to REGN, whose success is heavily dependent on its ophthalmology and oncology drugs, helps assess its risks compared to more diversified pharma giants.
Daily change in the price of a broad market stock, index - GURU.Markets
Regeneron is a leading biotech company known for its eye and cancer treatments. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in the industry, allowing one to assess how REGN's performance compares to overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Regeneron Pharmaceuticals
Regeneron is a leading biotech company known for its eye and skin treatments. Its year-over-year performance reflects both the commercial success of its existing blockbusters and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Heart
Regeneron Pharmaceuticals, Inc. is a biotech company known for its breakthrough drugs for eye diseases and dermatitis. Its success is built on a strong scientific platform. This chart shows how its innovation pipeline compares with that of larger, more diversified pharmaceutical companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Regeneron Pharmaceuticals is a biotech giant whose success depends on scientific breakthroughs, not economic cycles. Its stock performance is driven by clinical trial results and blockbuster sales of drugs like Eylea. A comparison with the market demonstrates how medical innovation can create value in any phase of economic activity.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Regeneron Pharmaceuticals
Regeneron, a biotech company, lives to the rhythm of clinical trials and blockbuster sales. The monthly fluctuations on the chart reflect news about new drug trials, sales data for its key drug Eylea, and strategic partnerships with other pharmaceutical giants.
Monthly dynamics of market capitalization of the market segment - Heart
This chart reflects the dynamics of the biotech sector. For Regeneron, one of the largest biotech companies, it's the backdrop. Its movements show how the company, thanks to the success of its blockbuster Eylea and strong R&D, has demonstrated growth amidst the overall sector's volatility.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Regeneron is one of the world's leading biotech companies, known for its breakthrough drugs for eye diseases, cancer, and inflammatory conditions. The chart below shows the overall market sentiment. Is Regeneron living up to its own standards, defined by clinical trial successes?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Regeneron Pharmaceuticals
Regeneron Pharmaceuticals shares are a weekly drama of biotech innovation. Price movements are heavily dependent on clinical trial results, regulatory decisions, and sales news for key drugs. This chart shows how investors evaluate the company's scientific breakthroughs and commercial risks.
Weekly dynamics of market capitalization of the market segment - Heart
The biopharmaceutical sector is a rollercoaster, where the entire industry's weekly performance can hinge on breakthrough news from a single company. Key clinical trial results and regulatory decisions set the tone for everyone. This chart illustrates this backdrop, with Regeneron's successes particularly striking.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Regeneron is a leading biotech company known for its innovative drugs. Shares in this sector often take on a life of their own, reacting to clinical trial data. This chart will help you understand: do Regeneron shares follow the broader market, or do news about its developments create a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
REGN - Market capitalization of the company Regeneron Pharmaceuticals
Regeneron's market capitalization chart is a tale of triumphant scientific innovation in biotechnology. Its surges often coincide with successful clinical trials and approvals of new blockbuster drugs. Its share price dynamics reflect the market's assessment of the company's powerful research platform and its ability to create drugs that change the lives of millions of patients.
REGN - Share of the company's market capitalization Regeneron Pharmaceuticals within the market segment - Heart
Regeneron is a biotech giant known for its innovative drugs, particularly in ophthalmology and immunology. Its significant market share reflects the success of blockbusters like Eylea. The company's weight chart tells the story of a scientific breakthrough that turned into a commercial success and changed approaches to disease treatment.
Market capitalization of the market segment - Heart
Regeneron is one of the leading innovative biopharmaceutical companies. The chart below shows the overall market capitalization of this science-intensive sector. Its dynamics reflect not only the general sentiment in healthcare but also investor confidence in scientific breakthroughs capable of generating multibillion-dollar blockbusters, for which Regeneron is renowned.
Market capitalization of all companies included in a broad market index - GURU.Markets
Regeneron is a biotech giant creating life-changing medicines. Its market capitalization isn't just a financial metric, but a measure of its hopes for scientific breakthroughs in medicine. Every success the company achieves creates waves in the market, demonstrating how innovation in healthcare is becoming a powerful economic force.
Book value capitalization of the company, segment and market as a whole
REGN - Book value capitalization of the company Regeneron Pharmaceuticals
Regeneron's balance sheet consists of its cutting-edge laboratories, biotech manufacturing facilities, and a portfolio of patents for life-saving drugs. This is real, science-intensive capital that drives modern medicine forward. How did the company build on this innovative foundation? The chart below clearly demonstrates its growth dynamics.
REGN - Share of the company's book capitalization Regeneron Pharmaceuticals within the market segment - Heart
Regeneron achieves breakthroughs in biotechnology, backed by cutting-edge research facilities and manufacturing laboratories. This chart reflects the share of these unique and valuable assets in the sector, demonstrating the material foundation upon which scientific discoveries are built.
Market segment balance sheet capitalization - Heart
Biotechnology is primarily about intellectual capital, but Regeneron's success also requires significant physical assets. Its advanced research facilities and manufacturing sites make it more capital-intensive than many R&D startups in its sector.
Book value of all companies included in the broad market index - GURU.Markets
Regeneron's assets aren't just machines, but cutting-edge biotech laboratories and manufacturing facilities where innovative drugs are developed and produced. The company's book value reflects its scientific and manufacturing potential in the fight against complex diseases. The chart shows the pharmaceutical company's physical weight in the industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Regeneron Pharmaceuticals
Regeneron's market capitalization is many times greater than the value of its laboratories. Investors are paying for its scientific platform, which can rapidly create breakthrough drugs like Eylea, and for its pipeline of future blockbusters. The chart shows a huge premium for this scientific pipeline.
Market to book capitalization ratio in a market segment - Heart
Regeneron is a biotech company whose future depends on the success of its scientific research. Its value lies in its pipeline of drugs and future discoveries. This chart shows the enormous premium investors are willing to pay for its scientific potential, valuing the company significantly above the value of its laboratories.
Market to book capitalization ratio for the market as a whole
Regeneron is a biotech company known for its innovative drugs. Its market value is determined not by its lab buildings, but by its portfolio of successful drugs and promising developments in its pipeline. This chart shows the huge premium that investors value companies capable of creating patented blockbusters that transform medicine.
Debts of the company, segment and market as a whole
REGN - Company debts Regeneron Pharmaceuticals
Regeneron Pharmaceuticals funds its cutting-edge biotech research and drug development primarily through robust cash flow from existing products. The company maintains low debt, giving it the flexibility to pursue major investments or acquisitions. This chart demonstrates a financial strategy based on operational self-sufficiency.
Market segment debts - Heart
Regeneron is a biotech company known for its innovative drugs for treating eye diseases, cancer, and inflammation. Drug development is a long and expensive process. This chart shows the company's financial strategy: whether it uses debt to fund clinical trials and acquisitions or prefers to rely on revenue from already successful drugs.
Market debt in general
Regeneron is a biotech company known for its innovative drugs. Developing new drugs is a lengthy and expensive process, requiring significant investment in R&D. This chart helps us understand how Regeneron funds its research—either through equity or debt—compared to the market, demonstrating its financial independence and confidence in its developments.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Regeneron Pharmaceuticals
Regeneron, a biotech company whose value is based on successful research, typically has a low debt load. This chart shows its financial structure. An increase in debt could signal major investments, partnerships, or share buybacks, and it's important for investors to understand how this relates to the risks and prospects of its R&D portfolio.
Market segment debt to market segment book capitalization - Heart
Regeneron Pharmaceuticals, a biotech company known for its breakthrough drugs, invests heavily in research and development. This chart shows the ratio of its debt to the total book value of its entire pharmaceutical sector. It helps us understand how the company's financial policies are dependent on the success of its developments and how they differ from those of major pharma giants.
Debt to book value of all companies in the market
Regeneron, a leading biotech company, invests heavily in research and development. This chart compares its debt position to the overall market capitalization. It allows one to assess how the company's financial strategy, dependent on the success of years of development, differs from overall market trends.
P/E of the company, segment and market as a whole
P/E - Regeneron Pharmaceuticals
Regeneron is a biotech company known for its innovative drugs for treating eye diseases, cancer, and inflammation. This chart shows the premium investors are willing to pay for its strong pipeline and successful blockbusters. The high valuation reflects expectations for future breakthroughs and commercialization of new drugs.
P/E of the market segment - Heart
Regeneron is a biotech company known for its breakthrough drug development for eye diseases, cancer, and inflammatory conditions. It's a science-intensive business with high potential. This chart reflects the average valuation in the pharmaceutical sector, helping to understand how investors view Regeneron's scientific pipeline and commercial success.
P/E of the market as a whole
Regeneron is a biotech company known for its breakthrough drugs. The valuation of such companies often depends on the success of clinical trials rather than on overall market trends. Does comparing this chart reveal how insulated Regeneron is from market sentiment? Or do breakthrough technologies attract investors even in a down market?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs, particularly for the treatment of eye diseases. This chart reflects analyst expectations for the success of its current blockbusters and future drugs in development. It assesses the company's scientific potential and future breakthroughs.
%20P%2FE%20Regeneron%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Regeneron-Pharmaceuticals&v=1772656026592 "Chart of the company's future (projected) P/E Regeneron Pharmaceuticals")
Future (projected) P/E of the market segment - Heart
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs for treating eye diseases, asthma, and cancer. The data presented reflects analysts' forecasts for its future profitability relative to the pharmaceutical sector. This reflects market confidence in the success of its current blockbusters and the potential of new developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772656026607 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Regeneron is a biotech company known for its innovative drugs. Its value is largely based on expectations of future discoveries and successful clinical trials. This market sentiment chart provides a backdrop against which investors evaluate the risks and potential of Regeneron's breakthrough scientific developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656026634 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Regeneron Pharmaceuticals
Regeneron is a biotech company known for its innovative medicines, particularly in ophthalmology and the treatment of inflammatory diseases. This chart shows the financial impact of scientific breakthroughs. The company's success is directly dependent on patent protection for key drugs and successful clinical trials of new developments.
Profit of companies in the market segment - Heart
Regeneron is a biotech company known for its innovative drugs for the treatment of eye diseases, cancer, and inflammatory conditions. This chart reflects the financial performance of the cardiology sector. The company's success depends on the results of clinical trials and the launch of new drugs, which are key growth drivers for the entire industry.
Overall market profit
Regeneron is a biotech company that creates innovative drugs to treat serious diseases. Demand for its key drugs isn't directly dependent on economic cycles, as health is a top priority. However, the overall state of the economy, which can be assessed using this chart, impacts government healthcare budgets and the ability of systems to cover expensive therapies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs, particularly for treating eye diseases. This chart shows analysts' expectations for future profits. The forecast depends largely on the sales success of existing blockbusters, such as Eylea, and the results of clinical trials of promising new drugs.
%20profit%20of%20the%20company%20Regeneron%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Regeneron-Pharmaceuticals&v=1772656026773 "Graph of future (projected) profit of the company Regeneron Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Heart
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs for the treatment of eye diseases, cancer, and inflammatory conditions. The pharmaceutical industry earnings forecast presented here reflects overall healthcare trends and allows one to assess how well Regeneron's robust pipeline can support above-average growth for the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772656026802 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs. While demand for drugs is less cyclical, the overall economic situation impacts government healthcare budgets and patients' ability to afford treatment. A positive outlook on this chart creates a favorable backdrop for the entire healthcare system.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656026808 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Regeneron Pharmaceuticals
Regeneron is a biotech company known for its innovative drugs for serious diseases. This chart shows how highly the market values its revenue from blockbuster drugs. A high value indicates investor confidence in the company's scientific potential and the future success of its research programs.
P/S market segment - Heart
Regeneron is a leading biotech company known for its innovative treatments for eye diseases, cancer, and inflammatory conditions. The company's revenue depends on the success of its research and the sales of blockbuster drugs. This chart shows the average valuation in the sector, which helps understand how the market values Regeneron's scientific potential and drug portfolio.
P/S of the market as a whole
Regeneron is a leading biotech company developing innovative drugs to treat serious diseases, including eye diseases and cancer. Its revenue depends on the success of clinical trials and the sales of blockbuster drugs. The chart below provides an insight into how the market values the revenue of this research-intensive company relative to the overall market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Regeneron Pharmaceuticals
Regeneron is a leading biotech company known for its innovative drugs, including blockbusters in ophthalmology. This chart shows how investors estimate future drug revenue. This estimate is heavily dependent on the success of current products and the market's confidence in the potential of its scientific developments and new clinical trials.
%20P%2FS%20Regeneron%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Regeneron-Pharmaceuticals&v=1772656026883 "The graph of the company's future (projected) P/S Regeneron Pharmaceuticals")
Future (projected) P/S of the market segment - Heart
Regeneron Pharmaceuticals is a biotech company known for developing innovative drugs, including those for eye diseases and cancer. The data presented compares the company's future revenue expectations with those of other pharmaceutical giants, demonstrating how investors view the potential of its current blockbusters and the prospects of new developments.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772656026926 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Regeneron is a biotech company known for its innovative drugs, including those for eye diseases and cancer. Its success depends on the results of clinical trials and patents, not on general economic cycles. This chart provides a general overview, but Regeneron's growth drivers lie in scientific breakthroughs and unmet medical needs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656026929 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Regeneron Pharmaceuticals
This chart illustrates the revenue of Regeneron Pharmaceuticals, a biotech company known for its innovative drugs. Revenue is generated through sales of medications, particularly those for the treatment of eye diseases and atopic dermatitis. Sales dynamics reflect the success of clinical trials, regulatory approvals, and demand for the company's medications from doctors and patients.
Sales of companies in the market segment - Heart
Regeneron is a biotech company known for its innovative treatments for eye diseases, cancer, and inflammatory conditions. Its success depends on the results of clinical trials and the commercialization of new drugs. This chart reflects pharmaceutical sector revenues. It shows the overall growth in healthcare costs and the demand for the breakthrough treatments Regeneron is developing.
Overall market sales
Regeneron Pharmaceuticals is a biotech company that develops innovative drugs for the treatment of serious diseases, including cardiology and oncology. Although demand for its drugs is less sensitive to short economic cycles, overall economic growth, as shown in the graph, ensures the stability of healthcare systems and their ability to afford expensive therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Regeneron Pharmaceuticals
Regeneron is a leading biotech company known for its innovative drugs, including those for eye diseases. This sales projection chart reflects analysts' expectations for demand for key drugs and the success of new developments. Revenue growth is driven by forecasts for the expansion of existing drugs and the launch of new ones.
%20sales%20of%20the%20company%20Regeneron%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Regeneron-Pharmaceuticals&v=1772656026967 "Schedule of future (projected) sales of the company Regeneron Pharmaceuticals")
Future (projected) sales of companies in the market segment - Heart
Regeneron is a leading biotech company that uses cutting-edge scientific research to create drugs for serious diseases, including eye diseases and oncology. This chart reflects revenue expectations for the entire pharmaceutical sector specializing in cardiovascular drugs, highlighting the overall trends in this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772656027024 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Regeneron Pharmaceuticals is a biotechnology company focused on developing innovative medicines. Although demand for its drugs for serious diseases is largely independent of the economy, overall market trends are important. Sustainable economic growth ensures the stability of healthcare systems and their ability to afford expensive treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656027026 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Regeneron Pharmaceuticals
Regeneron is a biotech company known for its innovative drugs for treating eye diseases, cancer, and inflammatory conditions. This chart reflects the high profitability typical of successful pharmaceutical companies with patented blockbusters. Sales success for key drugs directly determines the company's ability to generate significant profits.
Market segment marginality - Heart
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs for the treatment of eye diseases, cancer, and inflammation. Its success is determined by the profitability of its blockbusters and the effectiveness of its R&D. This chart shows the average profitability in the pharmaceutical industry. It helps assess the strength of Regeneron's drug portfolio and its scientific potential.
Market marginality as a whole
Regeneron Pharmaceuticals is a biotech company known for its innovative drugs. Its success depends less on the general economic cycles shown in the chart and more on the success of clinical trials. However, the overall economic situation influences public and private healthcare funding, which indirectly creates a favorable environment for growth.
Employees in the company, segment and market as a whole
Number of employees in the company Regeneron Pharmaceuticals
Regeneron is a biotech company known for its breakthrough drug development, including treatments for eye diseases and cancer. Science is about people. This chart shows the company's investment in human capital: scientists, researchers, and clinicians working to develop innovative treatments for serious diseases.
Share of the company's employees Regeneron Pharmaceuticals within the market segment - Heart
Regeneron Pharmaceuticals is a biotech company whose success is built on scientific discovery. Its drug manufacturing "factory" consists of laboratories staffed by world-class scientists. This metric measures its research and development strength, reflecting its share of the biotech sector's total workforce and highlighting its role as a major hub for scientific talent.
Number of employees in the market segment - Heart
Regeneron is a biotech company known for its breakthrough drug development, such as for treating retinal diseases. This chart demonstrates how science-intensive modern pharmaceuticals are. The growth of its research and development staff is directly linked to success in clinical trials and the expansion of its drug portfolio, which requires significant investment in R&D.
Number of employees in the market as a whole
Regeneron Pharmaceuticals is committed to cutting-edge scientific research. The growth of its staff of highly qualified scientists reflects not only the success of the company itself but also the dynamic development of the entire biotechnology industry—a key driver of modern medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Regeneron Pharmaceuticals (REGN)
Regeneron is a biotech giant that creates innovative medicines. Their market capitalization is built on scientific discoveries and patents. This chart demonstrates an R&D-driven business. Each of the company's scientists is worth billions of dollars in potential blockbusters, which is reflected in the extremely high market valuation per employee.
%20of%20the%20company%20Regeneron%20Pharmaceuticals%20(REGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Regeneron-Pharmaceuticals-REGN&v=1772656027263 "Chart of market capitalization per employee (in thousands of dollars) of the company Regeneron Pharmaceuticals (REGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Regeneron is a leading biotech company developing innovative drugs (such as Eylea). Its business relies 100% on R&D and successful clinical trials. This metric compares the market valuation per employee (primarily a scientist) to the industry average. A high value reflects the premium the market pays for each successful patent and the potential for future discoveries.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772656027276 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Regeneron Pharmaceuticals is a biotech company renowned for its innovative drugs. This metric clearly exemplifies its science-based model. Years of research and billions in R&D investments by its team of scientists translate into patented drugs with enormous market potential, which translates into the highest employee salaries.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656027291 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Regeneron Pharmaceuticals (REGN)
Regeneron is a biotech company known for its breakthrough drugs created using unique technologies (such as VelociSuite). Their business is pure science and R&D. This chart shows how successfully their discoveries are transformed into blockbusters. Their high profit per employee is a direct result of the high margins of their patented drugs.
%20Chart%20Regeneron%20Pharmaceuticals%20(REGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Regeneron-Pharmaceuticals-REGN&v=1772656027305 "Company Profit Per Employee (in thousands of dollars) Chart Regeneron Pharmaceuticals (REGN)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Regeneron is a biotech giant (Eylea's blockbuster). This chart sets the benchmark for "Pharma Holdings." The average profit per employee in this sector is astronomical. This is the "blockbuster business." A single successful drug patent can generate billions, more than recouping R&D costs and ensuring high profits per scientist.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772656027342 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Regeneron Pharmaceuticals is a biotechnology company that creates innovative medicines. Its main assets are scientific discoveries and intellectual property. This chart shows how research-intensive pharmaceuticals, where a single scientist can create a billion-dollar product, are profitable in terms of human capital.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656027461 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Regeneron Pharmaceuticals (REGN)
Regeneron is a biotech company known for its innovative drugs. This chart illustrates the economics of a successful pharmaceutical business. Astronomical revenue per employee is the result of commercializing blockbusters, where a small team of scientists and managers can create a product that generates billions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Regeneron-Pharmaceuticals-REGN&v=1772656027575 "Sales chart per company employee Regeneron Pharmaceuticals (REGN)")
Sales per employee in the market segment - Heart
Regeneron is a leading biotech company known for its breakthrough drugs (such as Eylea). Their business is science and R&D. Success depends on the productivity of their scientists, not on a massive workforce. This chart shows the average revenue per employee in the sector. It helps assess how efficient Regeneron's R&D machine is compared to others.
Sales per employee for the market as a whole
Regeneron is a leading biotech company known for its innovative drugs (such as Eylea). Their business is science and R&D, spending billions on discovering new treatments. This metric reflects how successful their team of scientists is in creating blockbusters. Their high revenue per employee is a result of selling high-margin, patented drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Regeneron Pharmaceuticals (REGN)
Regeneron is a biotech whose revenue depends heavily on blockbusters like the eye drug Eylea. This chart shows the volume of bets against it. Bears fear growing competition (biosimilars) for Eylea or the failure of new drugs in clinical trials, which threatens future growth.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Regeneron-Pharmaceuticals-REGN&v=1772656027671 "Short Shares Chart for the Company Regeneron Pharmaceuticals (REGN)")
Shares shorted by market segment - Heart
Regeneron is a leading biotech company known for its innovative drugs such as Eylea (for eyes) and Dupixent (for immunology). This metric reflects concerns. Short bets against Regeneron are often linked to patent risks. Investors may bet on the downside, fearing the loss of exclusivity for key blockbusters (like Eylea) and the emergence of cheaper alternatives (biosimilars), which would sharply reduce revenue.
Shares shorted by the overall market
Regeneron is a leading biotech company known for its breakthrough drugs (such as Eylea). Its stock price depends on R&D success. This indicator reflects overall "risk appetite." When investors panic, they flee risky biotechs whose valuations depend on future discoveries rather than current profits.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Regeneron Pharmaceuticals (REGN)
Regeneron is a biotech giant known for its blockbusters (like Eylea) and innovative R&D platform. This oscillator measures the reaction to binary events. Successful Phase 3 data for a new oncology drug can trigger explosive growth and euphoria, pushing the indicator above 70. Conversely, a failed trial would send it crashing into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Regeneron-Pharmaceuticals-REGN&v=1772656027844 "RSI 14 indicator chart for the company's stock Regeneron Pharmaceuticals (REGN)")
RSI 14 Market Segment - Heart
Regeneron is a biotech company known for its breakthrough drugs, including Eylea (for eyes) and Dupixent (for immunology). The RSI_14_Seg for their segment reflects the overall sentiment in biotech. The chart helps us understand: is REGN's growth a reflection of their R&D success, or is the entire biotech sector overheated by anticipation of new discoveries?
RSI 14 for the overall market
Regeneron (REGN) is a leading biotech company, known for its blockbuster eye drug Eylea and its strong scientific platform. Their business is science. This market sentiment chart can't stop blindness. Demand for Eylea is inelastic. In times of panic, investors value their stable cash flow and pipeline of drugs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast REGN (Regeneron Pharmaceuticals)
When forming a consensus forecast for Regeneron, analysts are looking beyond the horizon. Their target price is no longer as heavily dependent on the blockbuster Eylea (eye drug). This chart reflects their belief in the pipeline of new drugs, particularly in oncology and immunology. The consensus is an estimate of the company's R&D value.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-REGN-Regeneron-Pharmaceuticals&v=1772656027940 "A chart showing analyst consensus forecasts for the expected stock price. REGN (Regeneron Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price REGN (Regeneron Pharmaceuticals)
Regeneron (REGN) is a leading biotech company known for blockbusters like the eye treatment Eylea and the asthma drug Dupixent. This chart is a barometer of innovation. It shows the difference between the price and the consensus target, reflecting whether analysts believe the company's R&D pipeline can offset future competition for Eylea.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-REGN-Regeneron-Pharmaceuticals&v=1772656027981 "A chart showing the difference between the consensus forecast and the actual stock price. REGN (Regeneron Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Heart
Regeneron is a biotech company known for its blockbuster drug Eylea (an eye treatment) and a strong R&D platform (VelocImmune mice). This chart shows analysts' overall expectations for the entire biotech sector. It reflects whether industry experts see new breakthroughs or believe the sector has exhausted its growth drivers.
Analysts' consensus forecast for the overall market share price
Regeneron is a biotech company known for its breakthrough drug discovery methods (particularly in vision and oncology). Their success depends on science. However, overall market sentiment, visible in this chart, influences risk appetite. During periods of optimism, investors are more willing to fund the expensive and time-consuming R&D that Regeneron relies on.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Regeneron Pharmaceuticals
Regeneron is a leading biotech company known for its innovative drug development methods (VelocImmune mice). Their success is built on the blockbuster eye drug Eylea and the immunology drug Dupixent. This chart reflects the valuation of their R&D platform. It weighs current revenue from Eylea against the expected growth of Dupixent and their oncology pipeline.
AKIMA Market Segment Index - Heart
Regeneron Pharmaceuticals is a biotech company known for its breakthrough drugs developed using its proprietary technology (VelociSuite), including the blockbuster Eylea (for the eyes). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Regeneron's robust R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Regeneron is a leading biotech company, known for its breakthrough drugs (like the blockbuster Eylea eye treatment) and a robust R&D platform for discovering new antibodies. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative company, driven by science and patents, stacks up against the broader economic trends that influence investor sentiment in the healthcare sector.
